Agenus Inc. (AGEN)
| Market Cap | 300.74M +133.1% |
| Revenue (ttm) | 132.69M +30.5% |
| Net Income | 91.80M |
| EPS | 2.51 |
| Shares Out | 45.02M |
| PE Ratio | 2.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 815,424 |
| Open | 6.52 |
| Previous Close | 6.50 |
| Day's Range | 6.51 - 6.99 |
| 52-Week Range | 2.71 - 10.31 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 26.33 (+294.16%) |
| Est. Earnings | Nov 9, 2026 |
About AGEN
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte ... [Read more]
Financial Performance
In 2025, Agenus's revenue was $114.20 million, an increase of 10.37% compared to the previous year's $103.46 million. Losses were -$101,000, -99.96% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price target is $26.33, which is an increase of 294.16% from the latest price.
News
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Invest...
Agenus announces Armenia granted marketing authorizations for BOT+BAL
Agenus (AGEN) announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo, BOT, and Evamplix, BAL, each approved for use in combination with…
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has gra...
Agenus announces 3-year follow-up results from Phase 1b C-800-01 trial
Agenus (AGEN) announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab, Agenus’ multifunctional, Fc-enhanced ...
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of it...
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an F...
Agenus initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Agenus (AGEN) with a Buy rating and $19 price target The firm cites the potential for botensilimab plus balstilimab to establish a new perioperative…
Agenus initiated with a Buy at Chardan
Chardan initiated coverage of Agenus (AGEN) with a Buy rating and $40 price target The firm views Agenus as a “positively asymmetric immuno-oncology story.” The company is centered on its…
Agenus files to sell 221,525 shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 221,525 shares of common stock. The company is not selling any…
Agenus Registration statement: Registration filing
Agenus filed a registration statement on September 11, 2026, providing details about a securities offering with the SEC.
Agenus Transcript: Investor update
ROBBIN phase III neoadjuvant trial is progressing globally, with strong physician and investigator interest driven by durable BOT+BAL responses and expanding access programs. The study aims to reduce recurrences and chemotherapy needs in high-risk colon cancer, with robust infrastructure and product supply supporting rapid execution.
Agenus Slides: Investor update
Agenus has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-...
Agenus Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
BOT/BAL combination therapy has shown strong efficacy in MSS colon cancer, with phase III trials underway and robust financing secured. The addressable market exceeds $7B, and upcoming milestones include key trial readouts and data presentations.
Agenus to Participate in Upcoming September Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen...
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled ...
Agenus: No colorectal cancer recurrences observed at updated follow-up in trial
Agenus (AGEN) announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab, Agenus’ multifunctional, Fc-enhanced an...
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investig...
Agenus price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Agenus (AGEN) to $25 from $30 and keeps a Buy rating on the shares. The firm assumes the company will issue 23M…
Agenus files to sell 77.98M shares of common stock for holders
16:04 EDT Agenus (AGEN) files to sell 77.98M shares of common stock for holders
Agenus Registration statement: Registration filing
Agenus filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Agenus Earnings release: Q2 2026
Agenus released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Agenus Quarterly report: Q2 2026
Agenus has published its Q2 2026 quarterly earnings report on August 6, 2026.
Agenus concentrates resources on ROBBIN, discontinues commitment to BATTMAN
Agenus (AGEN) broadened authorized access to BOT+BAL during the second quarter through France’s national Autorisation d’Acces Compassionnel program and physician-led paid named-patient programs in add...
Agenus reports Q2 revenue $34.5M vs $25.7M last year
“The financing completed in July gives us a clear path to act on the clinical evidence supporting BOT+BAL in a large, underserved patient population,” said Garo H. Armen, Ph.D., Chairman…